Lenalidomide [clinicaltrials_resource:06d05bdce0327f674367fc70b3dfd2ce]
condition [clinicaltrials_vocabulary:condition]
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00044382]Phase 1 Study OF CDC-501 in Patients With Solid Tumors [clinicaltrials:NCT00046735]A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma [clinicaltrials:NCT00051116]Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma [clinicaltrials:NCT00055562]clinicaltrials:NCT00056160Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma. [clinicaltrials:NCT00057616]clinicaltrials:NCT00064038Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes [clinicaltrials:NCT00064974]clinicaltrials:NCT00065156Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma [clinicaltrials:NCT00065351]clinicaltrials:NCT00074282clinicaltrials:NCT00087672clinicaltrials:NCT00091260A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) [clinicaltrials:NCT00091624]Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II [clinicaltrials:NCT00093028]clinicaltrials:NCT00096044Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer [clinicaltrials:NCT00096525]clinicaltrials:NCT00098475Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors [clinicaltrials:NCT00100880]clinicaltrials:NCT00104962clinicaltrials:NCT00109005clinicaltrials:NCT00109772Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma [clinicaltrials:NCT00112827]clinicaltrials:NCT00114101Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy [clinicaltrials:NCT00120120]Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma [clinicaltrials:NCT00151203]clinicaltrials:NCT00153933Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme [clinicaltrials:NCT00165477]Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis [clinicaltrials:NCT00166413]Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy [clinicaltrials:NCT00179608]clinicaltrials:NCT00179621clinicaltrials:NCT00179647clinicaltrials:NCT00179660clinicaltrials:NCT00179673A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer [clinicaltrials:NCT00179686]Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer [clinicaltrials:NCT00179699]Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma [clinicaltrials:NCT00179725]clinicaltrials:NCT00227591clinicaltrials:NCT00238238Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00253344]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Lenalidomide [clinicaltrials_resource:06d05bdce0327f674367fc70b3dfd2ce]
Bio2RDF identifier
06d05bdce0327f674367fc70b3dfd2ce
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:06d05bdce0327f674367fc70b3dfd2ce
identifier
clinicaltrials_resource:06d05bdce0327f674367fc70b3dfd2ce
title
Lenalidomide
@en
type
label
Lenalidomide [clinicaltrials_resource:06d05bdce0327f674367fc70b3dfd2ce]
@en